Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, Uterine Myomas and Treatments, and Cervical Cancer and HPV Research.
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial
Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes
Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
Molecular profiles of endometrial cancer tumors among Black patients
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
RaPiDS (GOG-3028): Randomized Phase II Study of Balstilimab Alone or in Combination with Zalifrelimab in Cervical Cancer
Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
<i>BRCA1/2</i> Mutation Status Impact on Autophagy and Immune Response: Unheralded Target.
Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?
Values and worries of ovarian cancer patients
The limited utility of currently available venous thromboembolism risk assessment tools in gynecologic oncology patients
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study
ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling
Validation of a venous thromboembolism risk assessment model in gynecologic oncology
Gli1 Protein Regulates the S-phase Checkpoint in Tumor Cells via Bid Protein, and Its Inhibition Sensitizes to DNA Topoisomerase 1 Inhibitors
GLI1 upregulates C-JUN through a specific 130-kDa isoform